Open AccessTopical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults
Author(s) -
Hana M. El Sahly,
Robert L. Atmar,
Eli A. Sendra,
Ashley Wegel,
Wendy A. Keitel
Publication year - 2021
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiab206
Subject(s) - medicine , imiquimod , hemagglutination assay , influenza a virus subtype h5n1 , adjuvant , serology , vaccination , influenza vaccine , antibody titer , immunology , antibody , adverse effect , titer , hemagglutinin (influenza) , virology , virus
Safe, effective, and easy to deploy adjuvants are needed for influenza prepandemic preparedness. Based on recent reports, we hypothesized that preapplication of topical imiquimod followed by intradermal (ID) vaccination with monovalent inactivated influenza A/H5N1 vaccine (MIV A/H5N1) results in improved serologic responses.